Newer insights into the drug delivery approaches of α-glucosidase inhibitors

Expert Opinion on Drug Delivery

Volumn 9, Issue 4, 2012, Pages 403-416

  Kumar, Ruchita V ^a   Sinha, Vivek Ranjan ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

glucosidase inhibitors; Controlled release; Granules and hydrogels; Pellets; Side effects; Tablets

Indexed keywords

ACARBOSE; ALCOHOL; ALOGLIPTIN; ALPHA GLUCOSIDASE INHIBITOR; ALPHA TOCOPHEROL; DICAPRATE; DIETHYLHEXYLBUTAMIDOTRIAZONE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EMULSIFYING AGENT; ENSULIZOLE; ETHYLHEXYL TRIAZONE; EXENDIN 4; GLYCEROL; HEXADECANOL; LIRAGLUTIDE; MIGLITOL; PERFUME; PHENYL DIMETICONE; PRESERVATIVE; SAXAGLIPTIN; SITAGLIPTIN; TITANIUM DIOXIDE; UNCLASSIFIED DRUG; VILDAGLIPTIN; VOGLIBOSE; ZINC OXIDE;

ABDOMINAL DISTENSION; ATOPIC DERMATITIS; BORBORYGMUS; COMPETITIVE INHIBITION; DIABETES MELLITUS; DIARRHEA; DRUG DELIVERY SYSTEM; DRUG ELIMINATION; DRUG FORMULATION; DRUG GRANULE; DRUG HALF LIFE; DRUG PELLET; EMULSION; FLATULENCE; GASTROINTESTINAL SYMPTOM; HUMAN; HYDROGEL; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; NEURODERMATITIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATIENT COMPLIANCE; PHARMACODYNAMICS; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN INFLAMMATION; STOMACH FULLNESS;

ADMINISTRATION, ORAL; ALPHA-GLUCOSIDASES; BLOOD GLUCOSE; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; DIARRHEA; DRUG COMBINATIONS; DRUG DELIVERY SYSTEMS; DRUG IMPLANTS; ENZYME INHIBITORS; FLATULENCE; HUMANS; HYPOGLYCEMIC AGENTS; PATIENT COMPLIANCE; POSTPRANDIAL PERIOD; TABLETS;

EID: 84863407705     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2012.663080     Document Type: Review

References (93)

1. IDF. International diabetes federation. Diabetes Atlas. 4th edition. 2009
2. Davis SN, Granner DK. Insulin, oral hypoglycemic agents, and the pharmacology of the endocrine pancreas. Goodman & Gilman's Pharmacological Basis of Therapeutics. 11th edition. McGraw-Hill Medical Publishing Division; New York: 2006. p. 1635
3. Ceriello A. Postprandial hyperglycemia and diabetes complications. Diabetes 2005;54(1):1
4. Gerich JE. Clinical significance, pathogenesis, and management of postprandial hyperglycemia. Arch Intern Med 2003;163(11):1306 This paper focuses on the precipitating factors, degree of occurence, effects and management of postprandial hyperglycemia.
5. Gavin JR. Pathophysiologic mechanisms of postprandial hyperglycemia. Am J Cardiol 2001;88(6):4-8
6. Ratner RE. Controlling postprandial hyperglycemia. Am J Cardiol 2001;88(6):26-31
7. de Veciana M, Major CA, Morgan MA, et al. Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. N Engl J Med 1995;333(19):1237
8. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). JAMA 1999;281(21):2005
9. Nolte MS, Karam JH. Pancreatic hormones and antidiabetic drugs. Basic and Clinical Pharmacology. 10th edition. Mc-Graw Hill, New York, NY; 2007. p. 697-8
10. Lebovitz HE. Alpha-glucosidase inhibitors. Endocrinol Metab Clin North Am 1997;26(3):539
11. Scheen J, Lefebvre PJ. Oral antidiabetic agents: A guide to selection. Drugs 1998;55(2):225-36
12. Scheen AJ. Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus? Drugs 2003;63(10):933-51
13. Chiasson JL, Josse RG, Hunt JA, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus: A multicenter, controlled clinical trial. Ann Intern Med 1994;121(12):928
14. Johnston PS, Feig PU, Coniff RF, et al. Chronic treatment of African-American type 2 diabetic patients with alpha-glucosidase inhibition. Diabetes Care 1998;21(3):416
15. Welborn TA, Wearne K. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care 1979;2(2):154
16. Despres JP, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996;334(15):952
17. van de Laar FA, Lucassen PL. Akkermans RP, et al. -Glucosidase inhibitors for patients with type 2 diabetes. Diabetes Care 2005;28(1):154
18. Frommer W, Junge B, Keup U, et al. Amino sugar derivatives. Assigned to Bayer Aktiengesellschaft (DT). US4062950; 1977
19. Williams DA, Foye WO, Lemke TL. Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins, US; 2002
20. Muller L, Puls W. Pharmacology of alpha-glucosidase inhibitors. Structure and function of the small intestine Amsterdam. Excepta Med 1988;281-300
21. Ziese T, Kruger D, Grossklaus R. In vitro and in vivo inhibition of small intestinal digestion of sugar substitutes by acarbose. Aktuelle Ernahrungsmedizin 1995;20(4):229-31
22. Clissold SP, Edwards C. Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 1988;35(3):214 This paper covers in depth the pharmacodynamis and pharmacokinetic aspect of acarbose.
23. Putter J, Keup U, Krause H, et al. Pharmacokinetics of acarbose. Excerpta Med 1982;38
24. Ruppin H, Hagel J, Feuerbach W, et al. Fate and effects of the alpha-glucosidase inhibitor acarbose in humans. An intestinal slow-marker perfusion study. Gastroenterology 1988;95(1):93
25. Salehi A, Panagiotidis G, Borg LA, et al. The pseudotetrasaccharide acarbose inhibits pancreatic islet glucan-1, 4-Alpha-glucosidase activity in parallel with a suppressive action on glucose-induced insulin release. Diabetes 1995;44(7):830
26. Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial. Lancet 2002;359(9323):2072-7
27. Krause HP, Keup U, Thomas G, et al. Reduction of carbohydrate-induced hypertriglyceridemia in (fa, fa)' Zucker'rats by the a-glucosidase inhibitor acarbose (BAY g 5421). Metabolism 1982;31:710-14 This paper focuses on the role of Acarbose in the effective treatment of hypertriglyceridemia alongwith reduction in postprandial glucose.
28. Rosak C, Nitzsche G, Konig P, et al. The effect of the timing and the administration of acarbose on postprandial hyperglycaemia. Diabet Med 1995;12(11):979-84
29. Hillebrand I, Boehme K, Graefe KH, et al. The effect of new alpha-glucosidase inhibitors (Baym1099 and Bayo1248) on meal-stimulated increases in glucose and insulin levels in man. KIinische Wochenschrifi 1986;64:393-6
30. Scheppach W, Fabian C, Ahrens F, et al. Effect of starch malabsorption on colonic function and metabolism in humans. Gastroenterology 1988;95(6):1549
31. Pinol C, Guardiola E, Soler J, et al. A double blind, randomised, placebo controlled study to assess the maximum insulin dose reduction achieved with acarbose in the treatment of insulin-requiring type 2 diabetic patients. Diabetes Nutr Metab 1998;11(4):242-8
32. Cohen-Melamed E, Nyska A, Pollack A, et al. Aldose reductase (EC 1.1. 1.21) activity and reduced-glutathione content in lenses of diabetic sand rats (Psammomys obesus) fed with acarbose. Br J Nutr 1995;74(05):607-15
33. Takagi C, King GL, Clermont AC, et al. Reversal of abnormal retinal hemodynamics in diabetic rats by acarbose, an -glucosidase inhibitor. Curr Eye Res 1995;14(9):741-9
34. Junge B, Krause HP, Muller L, et al. Antidiabetic 3, 4, 5-trihydroxypiperidines. Assigned to Bayer Aktiengesellschaft. US4639436; 1987
35. Scott LJ, Spencer CM. Miglitol: A review of its therapeutic potential in type 2 diabetes mellitus. Drugs 2000;59(3):521-49
36. Schall R, Muller FO, Hundt HK, et al. Study of the effect of miglitol on the pharmacokinetics and pharmacodynamics of warfarin in healthy males. Arzneimittel-Forschung 1996;46(1):41
37. Kingma PJ, Menheere PP, Sels JP, et al. Alpha-Glucosidase inhibition by miglitol in NIDDM patients. Diabetes Care 1992;15(4):478
38. Ladas SD, Frydas A, Papadopoulos A, et al. Effects of alpha-glucosidase inhibitors on mouth to caecum transit time in humans. Gut 1992;33(9):1246
39. Pagano G, Marena S, Corgiat-Mansin L, et al. Comparison of miglitol and glibenclamide in diet-treated type 2 diabetic patients. Diab Metab 1995;21(3):162-7
40. Aoki K, Muraoka T, Ito Y, et al. Comparison of adverse gastrointestinal effects of acarbose and miglitol in healthy men: A crossover study. Intern Med 2010;49(12):1085-7
41. Aoki K, Miyazaki T, Nagakura J, et al. Effects of pre-meal versus post-meal administration of miglitol on plasma glucagon-like peptide-1 and glucosedependent insulinotropic polypeptide levels in healthy men. Endocr J 2010;57(8):673
42. Aoki K, Kato H, Terauchi Y. Divided-dose administration of miglitol just before and 15 minutes after the start of a meal smoothes postprandial plasma glucose excursions and serum insulin responses in healthy men. Endocr J 2007;54(6):1009-14
43. Masuda K, Aoki K, Terauchi Y. Effects of miglitol taken just before or after breakfast on plasma glucose, serum insulin, glucagon and incretin levels after lunch in men with normal glucose tolerance, impaired fasting glucose or impaired glucose tolerance. J Diabetes Investig 2011;2(6):435-40
44. Aoki K, Nakajima S, Nezu U, et al. Comparison of pre-vs. postmeal administration of miglitol for 3 months in type 2 diabetic patients. Diabetes Obes Metab 2008;10(10):970-2
45. Standl E, Schernthaner G, Rybka J, et al. Improved glycaemic control with miglitol in inadequately-controlled type 2 diabetics. Diabetes Res Clin Pract 2001;51(3):205-13
46. De Luis R. Utilidad del miglitol en pacientes con diabetes mellitus tipo 2 y mal control glucemico= usefulness of miglitol in patients with diabetes mellitus type 2 and insufficient control of the blood glucose. Rev Clin Esp 2004;204(1):32-4
47. Scheen AJ. Voglibose for prevention of type 2 diabetes mellitus. Lancet 2009;373(9675):1607-14
48. Horii S, Kameda Y, Fukase H. N-substituted pseudo-Aminosugars, their production and use. Google Patents 1987
49. Kawamori R, Tajima N, Iwamoto Y, et al. Voglibose Ph-3 Study Group. Voglibose for prevention of type 2 diabetes mellitus: A randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet 2009;373:1607-14
50. Shinozaki K, Suzuki M, Ikebuchi M, et al. Improvement of insulin sensitivity and dyslipidemia with a new [alpha]- glucosidase inhibitor, voglibose, in nondiabetic hyperinsulinemic subjectsß 1. Metabolism 1996;45(6):731-7
51. Yasuda K, Shimowada K, Uno M, et al. Long-term therapeutic effects of voglibose, a potent intestinal alpha-glucosidase inhibitor, in spontaneous diabetic GK rats. Diabetes Res Clin Pract 2003;59(2):113-22
52. Hirose T, Miyashita Y, Takagi M, et al. Characteristics of type 2 diabetic patients responding to voglibose administration as an adjunct to sulfonylurea. Diabetes Res Clin Pract 2001;54(1):9-15
53. Taira M, Takasu N, Komiya I, et al. Voglibose administration before the evening meal improves nocturnal hypoglycemia in insulin-dependent diabetic patients with intensive insulin therapy. Metabolism 2000;49(4):440-3
54. Vichayanrat A, Ploybutr S, Tunlakit M, et al. Efficacy and safety of voglibose in comparison with acarbose in type 2 diabetic patients. Diabetes Res Clin Pract 2002;55(2):99-104
55. Bae J, Jang C, Lee S. Methods for Pharmacodynamic analysis and proposed protocols for Bioequivalence Study of acarbose. Yakhak Hoeji 2007;51(6):440
56. Ahr HJ, Boberg M, Brendel E, et al. Pharmacokinetics of miglitol: Absorption, distribution, metabolism, and excretion following administration to rats, dogs, and man. Arzneimittel-Forschung 1997;47(6):734-45
57. Ibrahim FA, Ali FA, Ahmed SM, et al. Kinetic determination of acarbose and miglitol in bulk and pharmaceutical formulations using alkaline potassium permanganate. Int J Biomed Sci 2007;3:20-30; Back to cited text no. 2007;11
58. Mallikarjuna Rao N, Bagyalakshmi J, Ravi TK. Development and validation of spectrofluorimetric method for the estimation of voglibose in bulk and pharmaceutical dosage form. J Chem Pharma Res 2010;2:350-6
59. Melikian C, White TJ, Vanderplas A, et al. Adherence to oral antidiabetic therapy in a managed care organization: A comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther 2002;24(3):460-7
60. Ron Y, Wainstein J, Leibovitz A, et al. The effect of acarbose on the colonic transit time of elderly long-term care patients with type 2 diabetes mellitus. J Gerontol A Biol Sci Med Sci 2002;57(2):M111
61. Nahoko F, Kenji N, Akitoshi N, et al. Tablet containing acarbose. JP2009227658; 2009
62. Rosner H. Use for drug acarbose for weight control prevention of weight gain for weight loss for treatment and prevention of obesity. US6387361 2002
63. Morrison JU. Method and composition for controlled release acarbose formulations. Assigned to Morrison. US6849609; 2001
64. Blume H, Mutschler E, Weitschies W. Peroral dosage forms to achieve a sustained-release effect after medicament dosage with a meal. US20090010906; 2005
65. Devane J. Acarbose methods and formulations for treating chronic constipation. Assigned to AGI Therapeutics Research Limited. US20060229261; 2006
66. Kumar VD, Prakash TNKS, Easwari TS. Formulation, characterization and in-vitro evaluation of acarbose loaded ultra-deformable liposome gel for effective transdermal delivery. Adv Pharmacol Toxicol 2010;11:43-6
67. Sun G, Wu L. Acarbose Solid Sustained-Release Preparation and Preparing Method Thereof (CN200910016275). Assigned to Qingdao Huanghai Pharmaceutical Co, Ltd; 2009
68. Kumar GJ V, Badoni PP, Rawat MSM, Semalty A. Formulation and release kinetic study of hydrogel containing acarbose using polymers as hydroxypropylmethyl cellulose and guar gum. J Pharm Res 2009;2:370-4
69. Kumar GJ V, Badoni PP. Formulation and evaluation of matrix tablets of acarbose. Drug Invent Today 2010;2:264-7
70. Kumar RV, Sinha VR. A novel synergistic galactomannan-based unit dosage form for sustained release of acarbose. AAPS PharmSciTech 2012;1-14 This research paper helps in establishing the in vivo efficacy and improved safety profile of AGI on administration in controlled release dosgae form relative to immediate release dosage forms.
71. Koh N, Sakamoto S, Chino F. Improvement in medication compliance and glycemic control with voglibose oral disintegrating tablet. Tohoku J Exp Med 2008;216(3):249-57
72. Shimizu T, Sugaya M, Nakano Y. Rapidly disintegrable solid preparation. Assigned to Takeda Pharmaceutical Company Ltd. US7399485; 2008
73. Bechgaard H, Nielsen GH. Controlled-release multiple-units and single-unit doses a literature review. Drug Dev Ind Pharm 1978;4(1):53-67
74. Eskilson C. Controlled release by microencapsulation. Manufacturing Chem 1985;56(3):33-9
75. Ghebre-Sellassie I. Pharmaceutical pelletization technology. 1989
76. Tang ESK, Chan LW, Heng PWS. Coating of multiparticulates for sustained release. Am J Drug Deliv 2005;3(1):17-28
77. Odidi A, Odidi I. Extended release pharmaceuticals. US7858119; 2001
78. Deshpande MC, Venkateswarlu V, Babu RK, et al. Design and evaluation of oral bioadhesive controlled release formulations of miglitol, intended for prolonged inhibition of intestinal [alpha]-glucosidases and enhancement of plasma glucagon like peptide-1 levels. Int J Pharm 2009;380(1-2):16-24
79. Maes D, Declercq L, Corstjens H. Cosmetic compositions containing alpha glucosidase inhibitors and methods of use. WO2009038875; 2009
80. Ludger MCK, Claudia M, Thomas B, et al. Use of acarbose and its derivatives for treatment and prophylaxis of degenerative skin conditions. WO2003086420; 2003
81. Rosak C, Haupt E, Walter T, et al. The effect of combination treatment with acarbose and glibenclamide on postprandial glucose and insulin profiles: Additive blood glucose lowering effect and decreased hypoglycaemia. Diabetes Nutr Metabo 2002;15(3):143-51
82. Wagener G, Elmahdi K, Hohner U. Combination of acetylsalicylic acid and alpha-glucosidase inhibitors. US20070099850; 2004
83. Aoki K, Masuda K, Miyazaki T, et al. Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non-diabetic men. Endocr J 2010;57(8):667
84. Moritoh Y, Takeuchi K, Hazama M. Combination treatment with alogliptin and voglibose increases active GLP-1 circulation, prevents the development of diabetes and preserves pancreatic beta-cells in prediabetic db/db mice. Diabetes Obes Metab 2010;12(3):224-33
85. Chittora NC, Shrivastava A Jain A. New RP-HPLC method of miglitol in tablet dosage form including forced degradation studies and estimation in spiked rabbit plasma. J Young Pharmacists 2010;1 (4):364-70
86. Li X, Wang Y, Wang J, et al. Determination of miglitol in human plasma by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2007;21(2):247-51
87. Jain R, Lukram O Dwivedi A. Ultra performance liquid chromatography electrospray ionization-tandem mass spectrometry method for the estimation of miglitol in human plasma using metformin as the internal standard. Drug Test Anal 2010; 3 (4):255-62
88. Nirogi RVS, Kandikere VN, Shukla M, et al. Liquid chromatographic tandem mass spectrometry method for the quantification of miglitol in human plasma. Arzneimittelforschung. 2006;56(5):328-36
89. Wang F, Zhou J, Xiang D, et al. Determination of miglitol in human plasma by HPLC-MS/ESI. Chin Pharm J 2005;40 (1).
90. Woo JS Ryu JK. Quantitative determination of voglibose in pharmaceutical tablets using highperformance liquid chromatographyfluorescence detection with post-column derivatization and mass spectrometric detection. J Pharm Biomed Anal 2006;42(3):328-33
91. Rao NM, Kumar KR, Bagyalakshmi J, et al. RP-HPLC method development and validation for estimation of Voglibose in bulk and tablet dosage forms. Int J Res Pharm Sci 2010;1 (2):190-4
92. Xin-rong W, Min S, Bi-mei H, et al. The application of HPLC-ELSD determination in the production of voglibose. Chin. J. Antibiot. 2009;12
93. Raman NV, Reddy KR, Prasad AVSS, et al. Development and validation of LC methods with visible detection using precolumn derivatization and mass detection for the assay of voglibose. Talanta 2009;77(5):1869-72